Methyltestosterone and Testosterone interaction
Methyltestosterone and Testosterone: both prescribing labels flag this combination with the strongest language, such as a contraindication, a boxed warning, or an instruction to avoid it.
Do not combine without a prescriber's guidance. The label language below is the strongest FDA uses.
What the FDA labels say
From the Methyltestosterone label · effective 2025-05-30
To date, epidemiologic studies and randomized controlled trials have been inconclusive for determining the risk of major adverse cardiovascular events (MACE), such as non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death, with the use of testosterone compared to non-use.
Testosterone products are not recommended for use in patients with uncontrolled hypertension.
Some studies, but not all, have reported an increased risk of MACE in association with use of testosterone replacement therapy in men.
Testosterone can increase blood pressure which can increase cardiovascular (CV) risk over time.
Monitor blood pressure periodically in men using testosterone products, especially in men with hypertension.
From the Testosterone (Tlando) label · effective 2026-02-25
Hepatic Adverse Effects Prolonged use of high doses of orally active 17-alpha-alkyl androgens (e.g., methyltestosterone) has been associated with serious hepatic adverse effects (peliosis hepatis, hepatic neoplasms, cholestatic hepatitis, and jaundice).
Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.
Open in the checkerNot medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.